{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:08:58Z","timestamp":1792483738571,"version":"4.5.0"},"reference-count":34,"publisher":"Oceanside Publications Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    There is currently no accepted biomarker for predicting which patients will experience relapse after discontinuation of omalizumab therapy.\n                    <jats:bold>Objective:<\/jats:bold>\n                    This retrospective study aimed to identify clinical and laboratory markers associated with\n chronic spontaneous urticaria relapse.\n                    <jats:bold>Methods:<\/jats:bold>\n                    \u201cRelapse\u201d was defined as a urticaria control test score of &lt;12 during the 6-month follow-up after treatment interruption after 24 weeks of therapy. Baseline demographic characteristics and laboratory values,\n including total immunoglobulin E (IgE), anti\u2010thyroid peroxidase (TPO), C-reactive protein (CRP), and complete blood cell count parameters, were compared between patients who did and patients who did not experience relapse.\n                    <jats:bold>Results:<\/jats:bold>\n                    In the cohort of 43 patients, relapse\n occurred in 13 (30.2%). There were no significant differences between the patients who relapsed and those who did not relapse with respect to gender, age, disease duration, disease activity, concomitant angioedema, chronic inducible urticaria, atopic comorbidity, total IgE levels, or CRP levels.\n The median anti-TPO level was significantly higher in the relapsed group (p =\u20090.039), with an optimal predictive cutoff value of 67 IU\/mL, with 62.5% sensitivity and 84.2% specificity (area under the curve 0.753; p =\u20090.041). Among the hematologic parameters, the mean platelet\n volume (MPV) was the only variable to differ significantly (p =\u20090.028), being lower in the relapsed group than in the non-relapsed group, and yielded an optimal cutoff value of 10.25 fL, with 92.3% sensitivity and 34.5% specificity (area under the curve 0.712; p =\u20090.03).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    In this retrospective, small-sample study, the anti-TPO level and MPV emerged as exploratory predictors of recurrence; however, their clinical utility requires validation in larger, prospective cohorts before implementation.\n                  <\/jats:p>","DOI":"10.2500\/aap.2026.47.250089","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:32:26Z","timestamp":1768019546000},"page":"32-39","source":"Crossref","is-referenced-by-count":4,"title":["Predictors of relapse after omalizumab withdrawal in chronic spontaneous urticaria: Role of baseline autoimmunity and hematologic indices: CSU Relapse After Omalizumab Withdrawal"],"prefix":"10.2500","volume":"47","author":[{"given":"Sema","family":"Koc Yildirim","sequence":"first","affiliation":[{"name":"From the Department of Dermatology and Venereology, Usak University Faculty of Medicine, Usak, Turkey and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"Erbagci","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Venereology, Usak University Faculty of Medicine, Usak, Turkey and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neslihan","family":"Demirel Ogut","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Venereology, Usak University Faculty of Medicine, Usak, Turkey and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simge","family":"Unal","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Venereology, Usak University Faculty of Medicine, Usak, Turkey and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"Gokyayla","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Usak Training and Research Hospital, Usak, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"100533","DOI":"10.1016\/j.waojou.2021.100533","article-title":"The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management","volume":"14","author":"S\u00e1nchez-Borges","year":"2021","journal-title":"World Allergy Organ J"},{"key":"B2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"B3","first-page":"1","article-title":"Turkish guideline for the diagnosis and management of urticaria \u2013 2016","volume":"10(Suppl 1)","author":"G\u00f6nc\u00fc","year":"2016","journal-title":"Turk J Dermatol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jaci.2017.10.018","article-title":"The XTEND-CIU study: long-term use of omalizumab in chronic idiopathic urticaria","volume":"141","author":"Maurer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jaci.2024.11.039","article-title":"Chronic spontaneous urticaria remission definition and therapy stepping-down: World Allergy Organization position paper.","volume":"155","author":"Sanchez","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/all.16194","article-title":"Predicting relapse in chronic spontaneous urticaria: a retrospective cohort study evaluating omalizumab withdrawal regimens","volume":"79","author":"Kucharczyk","year":"2024","journal-title":"Allergy"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jaip.2018.04.003","article-title":"Predicting Clinical Trial. Predicting chronic spontaneous urticaria symptom return after omalizumab treatment discontinuation: Exploratory analysis","volume":"6","author":"Ferrer","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2217\/imt-2020-0088","article-title":"Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment","volume":"12","author":"Grieco","year":"2020","journal-title":"Immunotherapy"},{"key":"B9","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.jaci.2017.08.007","article-title":"Increased IgE levels are linked to faster relapse in patients with omalizumab-discontinued chronic spontaneous urticaria","volume":"140","author":"Ertas","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jdv.15350","article-title":"Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients","volume":"33","author":"Marzano","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"933913","DOI":"10.3389\/fcvm.2022.933913","article-title":"Systemic immune-inflammation index as a potential biomarker of cardiovascular diseases: a systematic review and meta-analysis","volume":"9","author":"Ye","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.4103\/idoj.IDOJ_499_19","article-title":"A real-world analysis of relapse rate and efficacy of a restricted monthly dose of omalizumab in recalcitrant chronic spontaneous urticaria in India","volume":"11","author":"Sardana","year":"2020","journal-title":"Indian Dermatol Online J"},{"key":"B13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ad.2024.08.014","article-title":"Redefining omalizumab discontinuation in chronic spontaneous urticaria: the value of optimization and predictive factors of relapse. a 52-week multicenter study","volume":"116","author":"Ceravalls","year":"2025","journal-title":"Actas Dermosifiliogr"},{"key":"B14","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1016\/j.jaip.2023.07.030","article-title":"Age and fast initial response predict omalizumab retreatment in chronic urticaria","volume":"11","author":"Meertens","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B15","doi-asserted-by":"crossref","first-page":"e15248","DOI":"10.1111\/dth.15248","article-title":"Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria","volume":"35","author":"Foti","year":"2022","journal-title":"Dermatol Ther"},{"key":"B16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000529250","article-title":"Analysis of the efficacy and recurrence of omalizumab use in the treatment of chronic spontaneous urticaria and chronic inducible urticaria","volume":"184","author":"Yu","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"e12752","DOI":"10.1111\/dth.12752","article-title":"Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: a retrospective study","volume":"32","author":"Serarslan","year":"2019","journal-title":"Dermatol Ther"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15586\/aei.v53i2.1207","article-title":"Factors associated with the efficacy of omalizumab treatment in chronic spontaneous urticaria","volume":"53","author":"Akku\u015f","year":"2025","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5415\/apallergy.0000000000000184","article-title":"A retrospective analysis of factors influencing response to omalizumab treatment in Indian patients with antihistamine refractory chronic spontaneous urticaria","volume":"15","author":"Prarthana","year":"2025","journal-title":"Asia Pac Allergy"},{"key":"B20","doi-asserted-by":"crossref","first-page":"100905","DOI":"10.1016\/j.waojou.2024.100905","article-title":"Omalizumab withdrawal outcomes in chronic spontaneous urticaria are linked with baseline IgE and eosinophil levels","volume":"17","author":"Maoz-Segal","year":"2024","journal-title":"World Allergy Organ J"},{"key":"B21","doi-asserted-by":"crossref","first-page":"20587384211065870","DOI":"10.1177\/20587384211065870","article-title":"Sex differences in the efficacy of omalizumab in the treatment of chronic spontaneous urticaria","volume":"35","author":"Sirufo","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2500\/aap.2022.43.220068","article-title":"Predictive factors of recurrence after omalizumab cessation in the elderly with urticaria: a real-life study","volume":"43","author":"Oztop","year":"2022","journal-title":"Allergy Asthma Proc"},{"key":"B23","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/jcm13154287","article-title":"Assessment of ELR, PLR, NLR and BLR ratios during omalizumab treatment of chronic spontaneous urticaria","volume":"13","author":"Branicka","year":"2024","journal-title":"J Clin Med"},{"key":"B24","doi-asserted-by":"crossref","first-page":"e15589","DOI":"10.1111\/dth.15589","article-title":"New markers to predict the response to omalizumab in chronic spontaneous urticaria","volume":"35","author":"Co\u015fansu","year":"2022","journal-title":"Dermatol Ther"},{"key":"B25","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3390\/jcm12072639","article-title":"Chronic urticaria treatment with omalizumab\u2014verification of NLR, PLR, SIRI and SII as biomarkers and predictors of treatment efficacy","volume":"12","author":"Tarkowski","year":"2023","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000444085","article-title":"The role of platelets in chronic urticaria","volume":"169","author":"Vena","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/09537104.2013.786822","article-title":"Platelet activation in chronic urticaria and its correlation with disease severity","volume":"25","author":"Chandrashekar","year":"2014","journal-title":"Platelets"},{"key":"B28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/cea.12870","article-title":"Potential blood biomarkers in chronic spontaneous urticaria","volume":"47","author":"Kolkhir","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"B29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5021\/ad.2019.31.4.467","article-title":"Mean platelet volume and mean platelet volume\/platelet count ratio in chronic urticaria","volume":"31","author":"Yim","year":"2019","journal-title":"Ann Dermatol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3906\/sag-1803-87","article-title":"Evaluation of platelet parameters and neutrophil\/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria","volume":"48","author":"Erta\u015f","year":"2018","journal-title":"Turk J Med Sci"},{"key":"B31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15569527.2018.1495227","article-title":"The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria","volume":"38","author":"Acer","year":"2019","journal-title":"Cutan Ocul Toxicol"},{"key":"B32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2500\/aap.2023.44.230051","article-title":"Interleukin-33, endothelin-1, and inflammatory parameters in chronic spontaneous urticaria","volume":"44","author":"Kulumbegov","year":"2023","journal-title":"Allergy Asthma Proc"},{"key":"B33","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.2500\/aap.2021.42.200088","article-title":"Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria","volume":"42","author":"Magen","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B34","doi-asserted-by":"crossref","first-page":"568","DOI":"10.5798\/dicletip.799661","article-title":"Can we predict the duration of treatment requirement by complete blood count in chronic spontaneous urticaria patients receiving omalizumab?","volume":"47","author":"Celik","year":"2020","journal-title":"Dicle Med J"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000001\/art00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:32:49Z","timestamp":1768019569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.250089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["1088-5412(20260101)47:1L.32;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.250089","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}